Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
NCT ID: NCT04994795
Last Updated: 2024-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
4000 participants
OBSERVATIONAL
2021-08-21
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
NCT05925751
Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer
NCT04589013
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
NCT06617390
Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
NCT07287904
Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer
NCT05425134
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab monotherapy
Predictive models (data collection)
Machine learning predictive models
Chemotherapy and pembrolizumab combination therapy
Predictive models (data collection)
Machine learning predictive models
Chemotherapy doublet
Predictive models (data collection)
Machine learning predictive models
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Predictive models (data collection)
Machine learning predictive models
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV)
* Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK)
* Cohort A: Received first line treatment with pembrolizumab monotherapy
* Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy
* Cohort C: Received first line treatment with chemotherapy doublet
Exclusion Criteria
* Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging)
* Patients participating in other clinical trials that modify the standard of care
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sophia Genetics SAS
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe Menu, MD-PhD, MBA
Role: STUDY_DIRECTOR
SOPHiA GENETICS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Holden Comprehensive Cancer Center at University of Iowa Health Care
Iowa City, Iowa, United States
UMASS Memorial Health
Worcester, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Carbone Comprehensive Cancer Center at University of Wisconsin
Madison, Wisconsin, United States
DASA - Hospital Brasilia
Brasília, , Brazil
DASA - Hospital de Niteroi
Niterói, , Brazil
DASA - Hospital São Lucas
Rio de Janeiro, , Brazil
DASA - Hospital Nove De Julho
São Paulo, , Brazil
AC Camargo
São Paulo, , Brazil
Sunnybrook Health Sciences Centre Toronto
Toronto, , Canada
Avicenne Hospital
Bobigny, , France
CHU Bordeaux
Bordeaux, , France
Ambroise Paré Hospital
Boulogne-Billancourt, , France
Hospices Civils de Lyon
Lyon, , France
CHU de Nantes
Nantes, , France
La Pitié Salpêtrière
Paris, , France
Tenon Hospital
Paris, , France
Foch Hospital
Suresnes, , France
Centre Hospitalier de Toulon
Toulon, , France
University Hospital Leipzig
Leipzig, , Germany
Shaare Zadek Medical Center
Jerusalem, , Israel
Sourasky Medical Center
Tel Aviv, , Israel
University Hospital Of Parma
Parma, , Italy
Policlinico Gemelli
Roma, , Italy
Azienda Sanitaria Universitaria Friuli Centrale (ASU FC)
Udine, , Italy
Fundacion jimenez diaz
Madrid, , Spain
Puerta De Hierro Hospital
Madrid, , Spain
Instituto Valenciano De Oncologia
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SGDLIV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.